Aeterna Zentaris (TSE:AEZS) has released an update.
Aeterna Zentaris has completed its Phase 3 DETECT-trial for macimorelin, a diagnostic test for Childhood Onset Growth Hormone Deficiency, with the last patient visit taking place in Europe. The study, which enrolled 100 subjects, is on track to report findings in Q3 2024. This achievement is a significant step for the company, potentially extending macimorelin’s use to pediatric diagnostics.
For further insights into TSE:AEZS stock, check out TipRanks’ Stock Analysis page.
